Dumfries family clocking up the miles to raise money for Cancer Research UK dailyrecord.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyrecord.co.uk Daily Mail and Mail on Sunday newspapers.
Thought LeadersDr. Emma Ward, Research Fellow,
University of East Anglia (UEA)
Yazan Sboul, Founder, Vaipio
AZoRobotics speaks with Dr. Emma Ward from UEA and Yazan Sboul from Vaipio about the development of the new smoking cessation device, LEVEL-X. A study (TRAJECT)
, carried out by the UEA has been funded by Cancer Research UK, this study looks at the smoking habits of dual-use smokers and aims at helping them quit for good.
Can you give our readers a summary of your recent research? What are the main aims of TRAJECT?
Emma: Smoking is still the biggest preventable cause of death worldwide. Regarding COVID-19, we know that smokers who catch the virus are more likely to suffer for longer with more severe symptoms. The best action a smoker can take to improve their health is to quit smoking.
SHEfinds
shefinds | Health
CBQ Method
As any other smoker and ex-smoker who believes in the mind over matter approach, I know of Nasia Davos and her work with habits coaching, self-development, and the CBQ Method.
I was searching for Davos’ Wikipedia page and saw many queries and reviews about her, so I dug in and found out everything I could. After joining her Facebook group, attending her webinars, watching her videos, reading dozens of her articles, interviews, reviews and just about everything written about her online, I put together a bio.
Early Life, Education and Background
Nasia Davos is a Greek – British author, psychologist, and life coach in her 30s who’s known for helping people become their best self by changing their mindset, overcoming addictions, and breaking behavioral and thinking patterns that hold them back.
About the AGILE Clinical Trial Platform On 13 February 2021, the Department of Health and Social Care announced a new initiative under which the UK government is providing millions of pounds of additional funding to expand the new AGILE clinical trial platform. The funding has been awarded by the Medical Research Council (MRC) and co-funded though the National Institute for Health Research (NIHR). This new platform will allow for global innovators to progress cutting-edge treatments for COVID-19 through all 3 clinical trial phases in the UK, further protecting our supply chain. This in turn will attract the brightest of researchers and manufacturers from around the world to trial their medicines here in Britain.